American Vanguard (AVD) 10-Q 31 Oct 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Oct. 24, 2014
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Trading Symbol	'AVD	'
Entity Registrant Name	'AMERICAN VANGUARD CORP	'
Entity Central Index Key	'0000005981	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	29,109,085

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Net sales	$71,635	$97,201	$221,043	$305,499
Cost of sales	43,342	54,042	137,785	166,493
Gross profit	28,293	43,159	83,258	139,006
Operating expenses	26,669	28,025	76,949	84,823
Operating income	1,624	15,134	6,309	54,183
Interest expense	804	464	2,292	1,712
Less interest capitalized	-25	-20	-56	-245
Income before income taxes and loss on equity investment	845	14,690	4,073	52,716
Income taxes expense	0	5,559	856	18,500
Income before loss on equity investment	845	9,131	3,217	34,216
Deduct net loss from equity method investment	-237	-386	-633	-386
Net income	608	8,745	2,584	33,830
Add back net loss attributable to non-controlling interest	124	125	452	341
Net income attributable to American Vanguard	732	8,870	3,036	34,171
Change in fair value of interest rate swaps	145	133	426	485
Foreign currency translation adjustment	-491	-126	-348	-195
Comprehensive income	$386	$8,877	$3,114	$34,461
Earnings per common share-basic	$0.03	$0.31	$0.11	$1.21
Earnings per common share-assuming dilution	$0.03	$0.31	$0.11	$1.18
Weighted average shares outstanding-basic	28,466	28,322	28,422	28,295
Weighted average shares outstanding-assuming dilution	28,797	28,889	28,888	28,890

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$5,045	$6,680
Receivables:	'	'
Trade, net of allowance for doubtful accounts of $434 and $392, respectively	89,287	74,060
Other	2,660	892
Total receivables	91,947	74,952
Inventories	171,520	139,830
Prepaid expenses	14,086	11,435
Income taxes receivable	2,414	10,088
Deferred income tax assets	6,521	6,521
Total current assets	291,533	249,506
Property, plant and equipment, net	51,214	52,468
Intangible assets, net of applicable amortization	102,192	107,007
Other assets	37,037	38,462
Total assets	481,976	447,443
Current liabilities:	'	'
Current installments of long-term debt	71	69
Current installments of other liabilities	1,397	2,132
Accounts payable	17,935	40,702
Deferred revenue	1,019	3,788
Accrued program costs	72,790	53,630
Accrued expenses and other payables	7,412	10,178
Total current liabilities	100,624	110,499
Long-term debt, excluding current installments	95,073	51,676
Other liabilities, excluding current installments	3,380	4,143
Deferred income tax liabilities	23,002	23,330
Total liabilities	222,079	189,648
Commitments and contingent liabilities	'	'
Stockholders' equity:	'	'
Preferred stock, $.10 par value per share; authorized 400,000 shares; none issued	'	'
Common stock, $.10 par value per share; authorized 40,000,000 shares; issued 31,554,063 shares at September 30, 2014 and 31,092,782 shares at December 31, 2013	3,156	3,109
Additional paid-in capital	65,038	60,160
Accumulated other comprehensive loss	-970	-1,048
Retained earnings	201,252	202,470
Total stockholders' equity including treasury stock	268,476	264,691
Less treasury stock, at cost, 2,450,634 shares at September 30, 2014 and 2,380,634 shares at December 31, 2013	-8,269	-6,738
American Vanguard Corporation stockholders' equity	260,207	257,953
Non-controlling interest	-310	-158
Total stockholders' equity	259,897	257,795
Total liabilities and stockholders' equity	$481,976	$447,443

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Allowance for doubtful accounts	$434	$392
Preferred stock, par value per share	$0.10	$0.10
Preferred stock, shares authorized	400,000	400,000
Preferred stock, shares issued	0	0
Common stock, par value per share	$0.10	$0.10
Common stock, shares authorized	40,000,000	40,000,000
Common stock, shares issued	31,554,063	31,092,782
Treasury stock, shares	2,450,634	2,380,634

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY (USD $)	Total	Common Stock	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive loss	Non- Controlling Interest	Treasury Stock
In Thousands, except Share data
Beginning Balance at Dec. 31, 2013	$257,795	$3,109	$60,160	$202,470	($1,048)	($158)	($6,738)
Beginning Balance (in shares) at Dec. 31, 2013	31,092,782	31,092,782	'	'	'	'	2,380,634
Stocks issued under ESPP (in shares)	'	16,446	'	'	'	'	'
Stocks issued under ESPP	393	2	391	'	'	'	'
Cash dividends on common stock	-1,417	'	'	-1,417	'	'	'
Foreign currency translation adjustment, net	51	'	'	'	51	'	'
Stock based compensation	768	'	768	'	'	'	'
Change in fair value of interest rate swaps	136	'	'	'	136	'	'
Stock options exercised and grants of restricted stock units	625	8	617	'	'	'	'
Stock options exercised and grants of restricted stock units, Shares	'	81,678	'	'	'	'	'
Excess tax benefits from share based payment arrangements	235	'	235	'	'	'	'
Shares repurchased (in shares)	'	'	'	'	'	'	70,000
Shares repurchased	-1,531	'	'	'	'	'	-1,531
Net income (loss)	2,005	'	'	2,159	'	-154	'
Ending Balance at Mar. 31, 2014	259,060	3,119	62,171	203,212	-861	-312	-8,269
Ending Balance (in shares) at Mar. 31, 2014	'	31,190,906	'	'	'	'	2,450,634
Cash dividends on common stock	-1,420	'	'	-1,420	'	'	'
Foreign currency translation adjustment, net	92	'	'	'	92	'	'
Stock based compensation	1,038	'	1,038	'	'	'	'
Change in fair value of interest rate swaps	145	'	'	'	145	'	'
Stock options exercised and grants of restricted stock units	178	34	144	'	'	'	'
Stock options exercised and grants of restricted stock units, Shares	'	337,494	'	'	'	'	'
Excess tax benefits from share based payment arrangements	27	'	27	'	'	'	'
Net income (loss)	-29	'	'	145	'	-174	'
Ending Balance at Jun. 30, 2014	259,091	3,153	63,380	201,937	-624	-486	-8,269
Ending Balance (in shares) at Jun. 30, 2014	'	31,528,400	'	'	'	'	2,450,634
Stocks issued under ESPP (in shares)	'	30,767	'	'	'	'	'
Stocks issued under ESPP	413	4	409	'	'	'	'
Cash dividends on common stock	-1,417	'	'	-1,417	'	'	'
Foreign currency translation adjustment, net	-491	'	'	'	-491	'	'
Stock based compensation	1,240	'	1,240	'	'	'	'
Change in fair value of interest rate swaps	145	'	'	'	145	'	'
Stock options exercised and grants of restricted stock units	7	-1	8	'	'	'	'
Stock options exercised and grants of restricted stock units, Shares	'	-5,104	'	'	'	'	'
Excess tax benefits from share based payment arrangements	1	'	1	'	'	'	'
Non-controlling interest contribution	300	'	'	'	'	300	'
Net income (loss)	608	'	'	732	'	-124	'
Ending Balance at Sep. 30, 2014	$259,897	$3,156	$65,038	$201,252	($970)	($310)	($8,269)
Ending Balance (in shares) at Sep. 30, 2014	31,554,063	31,554,063	'	'	'	'	2,450,634

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY (Parenthetical) (USD $)	3 Months Ended
	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014
Cash dividends on common stock, per share	$0.05	$0.05	$0.05

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities:	'	'
Net income	$2,584	$33,830
Adjustments to reconcile net income to net cash (used in) provided by operating activities:	'	'
Depreciation and amortization of fixed and intangible assets	11,996	11,183
Amortization of other long term assets	4,332	2,976
Amortization of discounted liabilities	249	130
Stock-based compensation	3,046	2,895
Tax benefit from exercise of stock options	-263	-57
Loss from equity method investment	633	386
Gain on dilution of equity method investment	-954	'
Changes in assets and liabilities associated with operations:	'	'
Increase in net receivables	-16,995	-34,304
Increase in inventories	-31,690	-39,221
Increase in prepaid expenses and other assets	-5,237	-14,564
Decrease (increase) in income tax receivable	7,937	-520
Decrease in deferred tax	-328	'
(Decrease) increase in accounts payable	-22,341	412
Decrease in deferred revenue	-2,769	-20,034
Increase in other payables and accrued expenses	15,964	64,088
Net cash (used in) provided by operating activities	-33,836	7,200
Cash flows from investing activities:	'	'
Capital expenditures	-5,947	-12,290
Investment	'	-3,687
Net cash used in investing activities	-5,947	-15,977
Cash flows from financing activities:	'	'
Net borrowings under line of credit agreement	43,450	38,750
Payments on long-term debt	'	-46,000
Payments on other long-term liabilities	-1,371	-1,415
Tax benefit from exercise of stock options	263	57
Decrease in other notes payable	'	-6,154
Repurchases of common stock	-1,531	'
Non-controlling interest contribution	300	'
Payment of cash dividends	-4,251	-3,390
Proceeds from the issuance of common stock (sale of stock under ESPP and exercise of stock options)	1,616	929
Net cash provided by (used in) financing activities	38,476	-17,223
Net decrease in cash and cash equivalents	-1,307	-26,000
Cash and cash equivalents as of the beginning of the period	6,680	38,476
Effect of exchange rate changes on cash and cash equivalents	-328	-151
Cash and cash equivalents as of the end of the period	$5,045	$12,325

Summary_of_Significant_Account

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2014
Summary of Significant Accounting Policies	'
	1. The accompanying unaudited condensed consolidated financial statements of American Vanguard Corporation and Subsidiaries (“AVD”) have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and with the instructions for Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation, have been included. Operating results for the nine months ended September 30, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014. For further information, refer to the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.

Property_plant_and_equipment

Property, plant and equipment	9 Months Ended
	Sep. 30, 2014
Property, plant and equipment	'
	2. Property, plant and equipment at September 30, 2014 and December 31, 2013 consists of the following:
		September 30,			December 31,
		2014			2013
	Land	$	2,458		$	2,458
	Buildings and improvements		14,356			14,167
	Machinery and equipment		106,559			94,184
	Office furniture, fixtures and equipment		4,844			9,717
	Automotive equipment		375			278
	Construction in progress		3,624			10,615
			132,216			131,419
	Less accumulated depreciation		(81,002	)		(78,951	)
		$	51,214		$	52,468
	During the three months ended September 30, 2014, the Company eliminated from assets and accumulated depreciation $5,150 of fully depreciated assets.
	Substantially all of the Company’s assets are pledged as collateral with its banks.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2014
Inventories	'
	3. Inventories are stated at the lower of cost or market. Cost is determined using the first-in, first-out method. The components of inventories consist of the following:
		September 30,		December 31,
		2014		2013
	Finished products	$	148,927	$	126,872
	Raw materials		22,593		12,958
		$	171,520	$	139,830

Segment_Reporting

Segment Reporting	9 Months Ended
	Sep. 30, 2014
Segment Reporting	'
	4. Based on similar economic and operational characteristics, the Company’s business is aggregated into one reportable product. Selective enterprise information is as follows:
		Three Months Ended				Nine Months Ended
		30-Sep				30-Sep
		2014		2013		2014		2013
	Net sales:
	Insecticides	$	24,626	$	49,539	$	105,587	$	167,624
	Herbicides/soil fumigants/fungicides		29,363		28,880		66,220		86,565
	Other, including plant growth regulators		10,711		9,189		23,447		26,108
			64,700		87,608		195,254		280,297
	Non-crop		6,935		9,593		25,789		25,202
		$	71,635	$	97,201	$	221,043	$	305,499
	Net sales:
	US	$	54,552	$	79,425	$	162,602	$	250,367
	International		17,083		17,776		58,441		55,132
		$	71,635	$	97,201	$	221,043	$	305,499

Accrued_Program_Costs

Accrued Program Costs	9 Months Ended
	Sep. 30, 2014
Accrued Program Costs	'
	5. Accrued Program Costs—In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 605, the Company classifies certain payments to its customers as a reduction of sales. The Company describes these payments as “Programs.” Programs are a critical part of doing business in the agricultural chemicals business market place. For accounting purposes, programs are recorded as a reduction in gross sales and include market pricing adjustments, volume take up or other key performance indicator-driven payments made to distributors, retailers or growers primarily at the end of a growing season. Each quarter management compares each sale transaction with published programs to determine what program liability has been incurred. Once this initial calculation is made for the specific quarter, sales and marketing management along with executive and financial management review the accumulated program balance and make assessments of whether or not customers are tracking in a manner that indicates that they will meet the requirements set out in the terms and conditions attached to each program. If management believes that customers are falling short of their annual goals, then periodic adjustments will be made to the accumulated accrual to properly reflect the Company’s best estimate of the liability at the balance sheet date. Programs are paid out predominantly on an annual basis, usually in the final quarter of the financial year or the first quarter of the following year.

Cash_Dividends

Cash Dividends	9 Months Ended
	Sep. 30, 2014
Cash Dividends	'
	6. The Company has issued the following cash dividends in the periods covered by this Form 10-Q:
	Declaration Date	Distribution Date	Record Date	Dividend		Total
				Per Share		Paid
	19-Sep-14	October 22, 2014	October 8, 2014	$	0.05	$	1,417
	9-Jun-14	17-Jul-14	3-Jul-14	$	0.05	$	1,420
	10-Mar-14	18-Apr-14	4-Apr-14	$	0.05	$	1,417
	Total			$	0.15	$	4,254
	9-Sep-13	18-Oct-13	4-Oct-13	$	0.05	$	1,415
	10-Jun-13	19-Jul-13	5-Jul-13	$	0.05	$	1,414
	11-Mar-13	19-Apr-13	5-Apr-13	$	0.07	$	1,976
	Total			$	0.17	$	4,805
	The Company announced the decision to begin making quarterly dividend payments on June 10, 2013. Previously, the Company made semi-annual dividend payments.

Earnings_Per_Share

Earnings Per Share	9 Months Ended
	Sep. 30, 2014
Earnings Per Share	'
	7. ASC260 Earnings Per Share (“EPS”) requires dual presentation of basic EPS and diluted EPS on the face of our condensed consolidated statements of operations and comprehensive income. Basic EPS is computed as net income divided by the weighted average number of shares of common stock outstanding during the period. Diluted EPS reflects potential dilution that could occur if securities or other contracts, which, for the Company, consists of options to purchase shares of the Company’s common stock, are exercised.
	The components of basic and diluted earnings per share were as follows:
		Three Months Ended				Nine Months Ended
		30-Sep				September 30
		2014		2013		2014		2013
	Numerator:
	Net income attributable to AVD	$	732	$	8,870	$	3,036	$	34,171
	Denominator:
	Weighted average shares outstanding-basic		28,466		28,322		28,422		28,295
	Dilutive effect of stock options and grants		331		567		466		595
			28,797		28,889		28,888		28,890
	The Company excluded 1,207 stock options from the computation of diluted earnings per share for the three months ended September 30, 2014 and 6,183 stock options from the computation of diluted earnings per share for the nine months ended September 30, 2014, because they are anti-dilutive. For the three and nine months ended September 30, 2013, no options were excluded from the computation.

Indebtedness

Indebtedness	9 Months Ended
	Sep. 30, 2014
Indebtedness	'
	8. The Company has a revolving line of credit and a note payable that together constitute the short-term and long-term loan balances shown in the condensed consolidated balance sheets at September 30, 2014 and December 31, 2013. These are summarized in the following table:
	Indebtedness	September 30, 2014										December 31, 2013
	$000’s	Long-term			Short-term			Total				Long-term				Short-term			Total
	Revolving line of credit	$	95,000		$	—		$	95,000			$	51,550			$	—		$	51,550
	Notes payable		73			71			144				126				69			195
	Total indebtedness	$	95,073		$	71		$	95,144			$	51,676			$	69		$	51,745
	On June 17, 2013, AMVAC Chemical Corporation (“AMVAC”), the Company’s principal operating subsidiary, as borrower, and affiliates (including the Company), as guarantors and/or borrowers, entered into a Second Amended and Restated Credit Agreement (the “New Credit Agreement”) with a group of commercial lenders led by Bank of the West (AMVAC’s primary bank) as agent, swing line lender and L/C issuer. The new facility also includes both AMVAC C.V. and AMVAC Netherlands BV (both Dutch subsidiaries) as borrowers. The New Credit Agreement supersedes the Amended and Restated Credit Agreement (“First Amendment”) dated as of January 10, 2011. The New Credit Agreement is a senior secured lending facility with a five year term and consists of a revolving line of credit up to $200 million and an accordion feature for up to $100 million. In connection with AMVAC’s entering into the New Credit Agreement, all outstanding indebtedness under the First Amendment was rolled over into the New Credit Agreement, including the conversion of term loans into revolving debt.
	On July 18, 2014, AMVAC, as borrower, and affiliates (including the Company), as guarantors and/or borrowers, entered into a First Amendment to Second Amended and Restated Credit Agreement (the “First Amendment”) with a group of commercial lenders led by Bank of the West (AMVAC’s primary bank) as agent, swing line lender and L/C issuer. Under the First Amendment, the Consolidated Funded Debt Ratio was increased for the third and fourth quarters of 2014 and the first quarter of 2015, and, further, borrowers are permitted to pay cash dividends to shareholders during the first and second quarters of 2015 notwithstanding prior net income levels.
	At September 30, 2014, the Company had in place one interest rate swap contract with a notional amount of $31,125 that is accounted for under FASB ASC 815 as a cash flow hedge. The effective portion of the gains or losses on the interest rate swap are reported as a component of other comprehensive income and reclassified into earnings in the same period or periods during which the hedged transactions affect earnings. Losses in other comprehensive income expected to be reclassified to earnings in the coming 12 months are $87. Amounts recorded in earnings for hedge ineffectiveness for the period ending September 30, 2014 were immaterial.
	The Company uses a pay fixed, receive 1 Month LIBOR (London Interbank Offered Rate) interest rate swap to manage the interest expense generated by variable rate debt. At September 30, 2014 and 2013, the Company had in place an interest rate swap, the use of which results in a fixed interest rate of 3.39% for the portion of variable rate debt that is covered by the interest rate swap contract. The current interest rate swap contract was put in place on March 30, 2011 and terminates on December 31, 2014.
	The following tables illustrate the impact of derivatives on the Company’s statements of operations and comprehensive income for the three months and nine months ended September 30, 2014.
	For the three months ended September 30, 2014 and 2013
	Derivatives in ASC 815	Amount of Gain or						Location of Gain or		Amount of Gain or (Loss)								Location of Gain or	Amount of Gain or
		(Loss) Recognized in						(Loss) Reclassified		Reclassified from Accumulated								(Loss) Recognized in	(Loss)
	Cash Flow	OCI on Derivative						from Accumulated		OCI into Income (Effective								Income on Derivative	Recognized
		(Effective Portion)						OCI into Income		Portion)								(Ineffective Portion)	in Income on
	Hedging Relationships							(Effective Portion)											Derivative
																			(Ineffective Portion)
		2014			2013					2014				2013					2014			2013
	Interest rate contracts	$	(1	)	$	(43	)	Interest Expense		$	(146	)		$	(176	)		Interest Expense	$	—		$	—
	Total	$	(1	)	$	(43	)			$	(146	)		$	(176	)			$	—		$	—
	For the nine months ended September 30, 2014 and 2013
	Derivatives in ASC 815	Amount of Gain or						Location of Gain or		Amount of Gain or (Loss)								Location of Gain or	Amount of Gain or
		(Loss) Recognized in						(Loss) Reclassified		Reclassified from Accumulated								(Loss) Recognized in	(Loss)
	Cash Flow	OCI on Derivative						from Accumulated		OCI into Income (Effective								Income on Derivative	Recognized
		(Effective Portion)						OCI into Income		Portion)								(Ineffective Portion)	in Income on
	Hedging Relationships							(Effective Portion)											Derivative
																			(Ineffective Portion)
		2014			2013					2014				2013					2014			2013
	Interest rate contracts	$	(32	)	$	(59	)	Interest Expense		$	(459	)		$	(543	)		Interest Expense	$	(0	)	$	(1	)
	Total	$	(32	)	$	(59	)			$	(459	)		$	(543	)			$	(0	)	$	(1	)
	The Company has three key covenants to its senior, secured credit facility with its banking syndicate. The covenants are as follows: (1) the Company must maintain its borrowings below a certain consolidated funded debt ratio, (2) the Company has a limitation on its annual spending on the acquisition of fixed asset capital additions, and (3) the Company must maintain a certain consolidated fixed charge coverage ratio. As of September 30, 2014, the Company met all covenants in that credit facility.
	At September 30, 2014, based on its performance against the most restrictive covenants listed above, the Company had the capacity to increase its borrowings by up to $51,156 under the credit facility agreement.
	The counterparty to the Company’s interest rate derivative financial instrument is Bank of the West, the Company’s primary bank. Pledged cash collateral is not required under the interest rate swap contract. At September 30, 2014, the Company did not hold any other derivative financial instruments. As a result, there occurs no offsetting of derivative liabilities in the Company’s condensed consolidated financial statements. The gross amount of derivative liabilities is equal to the net amount recognized in current installments of other liabilities in the condensed consolidated balance sheets, as shown in the below table:
												Gross Amounts Not Offset in the
												Statement of Financial Position
	Description	Gross			Gross			Net Amounts				Financial				Cash			Net Amount
		Amounts of			Amounts			of Liabilities				Instruments				Collateral
		Recognized			Offset in the			Presented in								Pledged
		Liabilities			Statement			the Statement
					of Financial			of Financial
					Position			Position
	Derivatives by counterparty:
	Bank of the West	$	(138	)	$	—		$	(138	)		$	—			$	—		$	(138	)
	Total	$	(138	)	$	—		$	(138	)		$	—			$	—		$	(138	)

Reclassification

Reclassification	9 Months Ended
	Sep. 30, 2014
Reclassification	'
	9. Reclassification—Certain items may have been reclassified in the prior period condensed consolidated financial statements to conform with the September 30, 2014 presentation.

Comprehensive_Income

Comprehensive Income	9 Months Ended
	Sep. 30, 2014
Comprehensive Income	'
	10. Total comprehensive income includes, in addition to net income, changes in equity that are excluded from the condensed consolidated statements of operations and are recorded directly into a separate section of stockholders’ equity on the condensed consolidated balance sheets. For the nine month period ended September 30, 2014, total comprehensive income consisted of net income attributable to AVD, the change in fair value of interest rate swaps and foreign currency translation adjustments.

Stock_Based_Compensation_Expen

Stock Based Compensation Expense	9 Months Ended
	Sep. 30, 2014
Stock Based Compensation Expense	'
	11. Stock Based Compensation Expense—The Company accounts for stock-based awards to employees and directors in accordance with FASB ASC 718, “Share-Based Payment,” which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors including shares of common stock granted for services, employee stock options, and employee stock purchases related to the Employee Stock Purchase Plan based on estimated fair values.
	Stock Options—During the nine months ended September 30, 2014, the Company did not grant any employees options to acquire shares of common stock.
	Option activity within each plan is as follows:
		Incentive			Weighted Average		Exercisable
		Stock Option			Price Per Share		Weighted
		Plans					Average
							Price
							Per Share
	Balance outstanding, December 31, 2013		561,029		$	7.76	$	7.7
	Options exercised, $7.50		(82,650	)		7.5
	Balance outstanding, March 31, 2014		478,379		$	7.8	$	7.74
	Options exercised, $7.50		(17,500	)		7.5
	Balance outstanding, June 30, 2014		460,879		$	7.81	$	7.77
	Options exercised, $7.50		(1,000	)		7.5
	Balance outstanding, September 30, 2014		459,879		$	7.81	$	7.81
	Information relating to stock options at September 30, 2014 summarized by exercise price is as follows:
		Outstanding Weighted Average							Exercisable Weighted
									Average
	Exercise Price Per Share	Shares			Remaining		Exercise		Shares		Exercise
					Life		Price				Price
					(Months)
	Incentive Stock Option Plan:
	$7.50		433,200			74	$	7.5		433,200	$	7.5
	$11.32—$14.75		26,679			71	$	12.9		26,679	$	12.9
			459,879				$	7.81		459,879	$	7.81
	The weighted average exercise prices for options granted and exercisable and the weighted average remaining contractual life for options outstanding as of September 30, 2014 was as follows:
		Number			Weighted		Weighted		Intrinsic
		of			Average		Average		Value
		Shares			Exercise		Remaining		(thousands)
					Price		Contractual
							Life
							(Months)
	As of September 30, 2014:
	Incentive Stock Option Plans:
	Outstanding		459,879		$	7.81		74	$	1,603
	Expected to Vest		459,879		$	7.81		74	$	1,603
	Exercisable		459,879		$	7.81		74	$	1,603
	During the three months ended September 30, 2014 and 2013, the Company recognized stock-based compensation expense, excluding expense associated with modifications, related to stock options of $0 and $201, respectively.
	During the nine months ended September 30, 2014 and 2013, the Company recognized stock-based compensation expense, excluding expense associated with modifications, related to stock options of $21 and $624, respectively.
	As of September 30, 2014, the Company had no unamortized stock-based compensation expenses related to unvested stock options outstanding. Stock-based compensation expense will change if any stock options are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures.
	Restricted Shares—A status summary of non-vested shares as of and for the nine months ended September 30, 2014 is presented below:
		Number			Weighted
		of			Average
		Shares			Grant-
					Date
					Fair Value
	Nonvested shares at December 31, 2013		376,702		$	24.85
	Vested		(1,000	)	$	31.83
	Forfeited		(1,840	)	$	24.23
	Nonvested shares at March 31, 2014		373,862		$	24.83
	Granted		240,724		$	14.81
	Vested		(23,478	)	$	13.84
	Nonvested shares at June 30, 2014		591,108		$	21.19
	Vested		(4,000	)	$	12.16
	Forfeited		(6,104	)	$	14.92
	Nonvested shares at September 30, 2014		581,004		$	21.32
	Restricted stock grants—During the nine months ended September 30, 2014, the Company granted a total of 240,724 shares of common stock. Of these, 23,478 shares vest immediately, and the balance will cliff vest after three years of service. The shares granted in 2014 were average fair valued at $14.81 per share. The fair value was determined by using the publicly traded share price as of the date of grant. The Company is recognizing as expense the value of restricted shares over the required service period.
	During the nine months ended September 30, 2013, the Company granted a total of 158,614 shares of common stock. Of these, 8,230 shares vested immediately and the balance of 148,884 shares will cliff vest after three years of service. The shares granted in 2013 were average fair valued at $31.06 per share. The fair value was determined by using the publicly traded share price as of the date of grant. The Company is recognizing as expense the value of restricted shares over the required service period.
	During the three months ended September 30, 2014 and 2013, the Company recognized stock-based compensation expense related to restricted shares of $1,139 and $856, respectively.
	During the nine months ended September 30, 2014 and 2013, the Company recognized stock-based compensation expense related to restricted shares of $2,958 and $2,153, respectively.
	As of September 30, 2014, the Company had approximately $6,069 of unamortized stock-based compensation expenses related to unvested restricted shares. This amount will be recognized over the weighted-average period of 1.9 years. This projected expense will change if any restricted shares are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures.
	Performance Based Shares—A status summary of non-vested performance based shares as of and for the nine months ended September 30, 2014 is presented below:
		Number			Weighted
of		Average
Shares		Grant-
		Date
		Fair Value
Nonvested shares at December 31, 2013		24,637		$	28.43
Vested		—		$	—
Forfeited		—		$	—
Nonvested shares at March 31, 2014		24,637		$	28.43
Granted		79,270		$	14.23
Vested		—		$	—
Forfeited		—		$	—
Nonvested shares at June 30, 2014		103,907		$	17.6
Granted		—		$	—
Vested		—		$	—
Forfeited		—		$	—
Nonvested shares at September 30, 2014		103,907		$	17.6
Performance Based Shares—During the nine months ended September 30, 2014, the Company granted a total of 79,270 performance based shares that will cliff vest on May 23, 2017, provided that recipient is continuously employed by the Company during the vesting period. Of these performance based shares, 80% are based upon financial performance of the Company, specifically, an earnings before interest and tax (“EBIT”) goal weighted at 50% and a net sales goal weighted at 30% for the period commencing April 1, 2014 and ending December 31, 2016; the remaining 20% of performance based shares are based upon AVD stock price appreciation (shareholder return) over the same performance measurement period. The net sales and EBIT goal measures the relative growth of the Company’s net sales and EBIT for the performance measurement period, as compared to the median growth of net sales and EBIT for an identified peer group. The shareholder return goal measures the relative growth of the fair market value of the Company’s stock price over the performance measurement period, as compared to that of the Russell 2000 Index and the median fair market value of the common stock of the comparator companies. All parts of these awards vest in three years, but are subject to reduction to a minimum (or even zero) for meeting less than the targeted performance and to increase to a maximum of 200% for meeting in excess of the targeted performance.
During the nine months ended September 30, 2013, the Company granted a total of 24,637 performance based shares that will cliff vest after three years of service. Of these performance based shares, 80% are based upon net sales and net income for the period commencing April 1, 2013 and ending December 31, 2015; the remaining 20% of performance based shares are based upon AVD stock price appreciation over the course of the period commencing June 6, 2013 and ending on December 31, 2015. Both parts of these awards vest in three years, but are subject to reduction to a minimum (or even zero) for meeting less than the targeted performance and to increase to a maximum of 200% for meeting in excess of the targeted performance.
The performance based shares related to net sales and EBIT were average fair valued at $14.92 per share. The fair value was determined by using the publicly traded share price as of the date of grant. The performance based shares related to AVD stock price were average fair valued at $12.85 per share. The fair value was determined by using the Monte Carlo valuation method. The Company is recognizing as expense the value of these shares over the required service period of three years.
During the three months ended September 30, 2014, the Company recognized stock-based compensation expense related to performance based shares of $101. During the three months ended September 30, 2013, the Company recognized stock-based compensation expense related to performance based shares of $92.
During the nine months ended September 30, 2014, the Company recognized stock-based compensation expense related to performance based shares of $67. During the nine months ended September 30, 2013, the Company recognized stock-based compensation expense related to performance based shares of $118.
As of September 30, 2014, the Company had approximately $1,404 of unamortized stock-based compensation expenses related to unvested performance based shares. This amount will be recognized over the weighted-average period of 2.4 years. This projected expense will change if any performance based shares are granted or cancelled prior to the respective reporting periods or if there are any changes required to be made for estimated forfeitures.

Legal_Proceedings

Legal Proceedings	9 Months Ended
	Sep. 30, 2014
Legal Proceedings	'
	12. Legal Proceedings—Summarized below are litigation matters in which there has been material activity or developments during the three month period ended September 30, 2014.
	A. DBCP Cases
	A number of suits have been filed against AMVAC, alleging injury from exposure to the agricultural chemical 1, 2-dibromo-3-chloropropane (“DBCP®”). DBCP was manufactured by several chemical companies, including Dow Chemical Company, Shell Oil Company and AMVAC, and was approved by the United States Environmental Protection Agency (“USEPA”) to control nematodes. DBCP was also applied on banana farms in Latin America. The USEPA suspended registrations of DBCP in October 1979, except for use on pineapples in Hawaii. The USEPA suspension was partially based on 1977 studies by other manufacturers that indicated a possible link between male fertility and exposure to DBCP among their factory production workers involved with producing the product. There are approximately 100 lawsuits, foreign and domestic, filed by former banana workers in which AMVAC has been named as a party. Fifteen of these suits have been filed in the United States (with prayers for unspecified damages) and the remainder have been filed in Nicaragua. All of these actions are in various stages and allege injury from exposure to DBCP, including claims for sterility. Except for the cases described below, there have been no material developments in these matters since the filing of the Company’s Form 10-Q for the period ended June 30, 2014.
	In what has been designated as the remaining Hendler-Delaware cases (involving claims for physical injury arising from alleged exposure to DBCP over the course of the late 1960’s through the mid-1980’s on behalf of about 2,700 banana plantation workers from Costa Rica, Ecuador, Guatemala and Panama – more fully described in the Company’s Form 10-K for the period ended December 31, 2013), on May 27, 2014, the district court granted defendant Dole’s motion to dismiss the matter without prejudice on the grounds that the applicable statutes of limitation had expired. Then, on August 5, 2014, the parties stipulated to summary judgment in favor of all defendants (on the same grounds as the earlier motion) and the court entered final judgment in the matter. On October 21, 2014 plaintiffs filed an appeal with the U.S. District Court of Appeals. The Company plans to oppose the appeal.
	Further, in Chaverri, the one Hendler-Delaware case that was filed with the Superior Court of the State of Delaware (as opposed to the United States District Court in Delaware), on October 20, 2014, the Supreme Court of the State of Delaware issued an order affirming the lower court’s dismissal of the action based upon passage of the statute of limitations.
	Also, in Blanco (Delaware state court matter involving one plaintiff who worked at a plantation in Costa Rica), in response to a motion for summary judgment filed by the Dole defendants on September 27, 2014 (based on expiration of the statute of limitations and inability to prove causation), on October 6, 2014, plaintiff agreed to dismiss the matter in its entirety with prejudice.
	B. Other Matters
	In Mark Spence v. A.W. Chesterton Company et al. (an asbestos exposure matter in an Illinois state court in which 46 defendants, including the Company, are named), after being informed that the Company has never used asbestos in either its products or packaging, plaintiff dismissed the matter without prejudice on September 22, 2014. Thus, this matter is now concluded.

Recently_Issued_Accounting_Gui

Recently Issued Accounting Guidance	9 Months Ended
	Sep. 30, 2014
Recently Issued Accounting Guidance	'
	13. Recently Issued Accounting Guidance—In August 2014, The Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. This ASU requires that management of an entity assesses whether there is substantial doubt about the ability of the entity to continue as a going concern and for making the appropriate disclosures. The assessment must be performed at each annual and interim reporting period, and there is substantial doubt about an entity’s ability to continue as a going concern if it is probable that the entity will be unable to meet its obligation as they become due within 12 months of the date of the financial statements are issued. In the assessment, management must consider the information available at the date of issuance of the financial statements, as well as mitigating factors and plans to alleviate the substantial doubt. ASU 2014-15 is effective for annual period ending after December 15, 2016 and interim periods thereafter.
	In June 2014, FASB issued ASU 2014-12, Compensation—Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period, a consensus of the FASB Emerging Issues Task Force. ASU 2014-12 requires that a performance target that affects vesting of share-based payment awards and that could be achieved after the requisite service period be treated as a performance condition. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the periods for which the requisite service has already been rendered. If the performance target becomes probable of being achieved before the end of the requisite service period, the remaining unrecognized compensation cost should be recognized prospectively over the remaining requisite service period. The total amount of compensation cost recognized during and after the requisite service period should reflect the number of awards that are expected to vest and should be adjusted to reflect those awards that ultimately vest. The requisite service period ends when the employee can cease rendering service and still be eligible to vest in the award if the performance target is achieved. ASU 2014-12 is effective for all entities for interim and annual periods beginning after December 15, 2015, with early adoption permitted. An entity may apply the amendments in ASU 2014-12 either (i) prospectively to all awards granted or modified after the effective date or (ii) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. The adoption of ASU 2014-12 is not expected to have a material impact on the Company’s consolidated financial condition or results of operations.
	In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers. ASU 2014-09 outlines a new, single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. This new revenue recognition model provides a five-step analysis in determining when and how revenue is recognized. The new model will require revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration a company expects to receive in exchange for those goods or services. The standard is effective for annual periods beginning after December 15, 2016, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). We are currently evaluating the impact of our pending adoption of ASU 2014-09 on our consolidated financial statements and have not yet determined the method by which we will adopt the standard in 2017 or its impact on our consolidated financial statements.

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2014
Fair Value of Financial Instruments	'
	14. Fair Value of Financial Instruments—The carrying values of cash, receivables and accounts payable approximate their fair values because of the short maturity of these instruments. The fair value of the Company’s long-term debt and note payable to bank is estimated based on the quoted market prices for the same or similar issues or on the current rates offered to the Company for debt of the same remaining maturities. Such fair value approximates the respective carrying values of the Company’s long-term debt and note payable to bank.
	The Company’s cash flow hedge related to a variable debt instrument is measured at fair value on a recurring basis, and the balances as of September 30, 2014 and December 31, 2013 (which are included in other liabilities in the condensed consolidated balance sheets) were as follows:
			Fair Value Measurements
			Using Input Type
			Level 1		Level 2		Level 3
	As of September 30, 2014:
	Liability:
	Interest rate derivative financial instruments (1)		$	—	$	138	$	—
	As of December 31, 2013:
	Liability:
	Interest rate derivative financial instruments (1)		$	—	$	564	$	—
	-1	Includes accrued interest expense
	The valuation techniques used to measure the fair value of the derivative financial instruments above in which the counterparties have high credit ratings, were derived from pricing models, such as discounted cash flow techniques, with all significant inputs derived from or corroborated by observable market data. The Company’s discounted cash flow techniques use observable market inputs, such as LIBOR-based yield curves and foreign currency forward rates.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Loss	9 Months Ended
	Sep. 30, 2014
Accumulated Other Comprehensive Loss	'
	15. Accumulated Other Comprehensive Loss—
	The following table lists the beginning balance, annual activity and ending balance of each component of accumulated other comprehensive loss:
		Interest			FX			Total
		Rate			Translation
		Swap
	Balance, December 31, 2013	$	(340	)	$	(708	)	$	(1,048	)
	Other comprehensive loss before reclassifications		(23	)		51			28
	Amounts reclassified from AOCI		159			—			159
	Balance, March 31, 2014	$	(204	)	$	(657	)	$	(861	)
	Other comprehensive loss before reclassifications		(8	)		92			84
	Amounts reclassified from AOCI		153			—			153
	Balance, June 30, 2014	$	(59	)	$	(565	)	$	(624	)
	Other comprehensive loss before reclassifications		—			(491	)		(491	)
	Amounts reclassified from AOCI		145			—			145
	Balance, September 30, 2014	$	86		$	(1,056	)	$	(970	)

Equity_Investment

Equity Investment	9 Months Ended
	Sep. 30, 2014
Equity Investment	'
	16. On March 25, 2013, the Company made a $3,687 equity investment in TyraTech Inc. (“TyraTech”), a Delaware corporation that specializes in developing, marketing and selling pesticide products containing essential oils and other natural ingredients, to acquire an ownership position of approximately 29.27%. In February 2014, TyraTech issued 37,391,763 shares, raising approximately £1.87 ($3.1) million and issued 50,000,000 shares in July 2014 raising approximately £3.5 ($5.9) million. Due to the share issuance in both periods, the Company recognized a $954 gain from the dilution of the Company’s ownership position. Following the issuances of these new shares, as of September 30, 2014, the Company’s ownership position in TyraTech was approximately 19.28%. The Company utilizes the equity method of accounting with respect to this investment. As a result, our net income includes losses from equity method investments which represents our proportionate share of TyraTech’s estimated net losses for the current accounting period. For the nine months ended September 30, 2014, the Company recognized an operating loss of $633 ($237 for the three months ended September 30, 2014) as a result of the Company’s ownership position in TyraTech.
	The Company’s investment in TyraTech is included in other assets on the condensed consolidated balance sheets. At September 30, 2014, the carrying value of the Company’s investment in TyraTech was $3,022, and the quoted market value of its shareholding was $6,321 based on the London Stock Exchange, Alternative Investment Market (“AIM”).

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2014
Income Taxes	'
	17. Income Taxes—Income tax expense was $856 for the nine months ended September 30, 2014 as compared to $18,500 for the nine months ended September 30, 2013. The effective tax rate was 21% in 2014 and 35% in 2013. There is no income tax for the three months ended September 30, 2014, and an income tax expense of $5,559 for the three months ended September 30, 2013.
	The effective tax rate for the three months ended September 30, 2014 is based on the projected income for the full year and is subject to ongoing review and adjustment by management.

Subsequent_event

Subsequent event	9 Months Ended
	Sep. 30, 2014
Subsequent event	'
	18. Subsequent event—October 1, 2014, the Company exercised warrants in the amount of $500 and purchased 6,155,000 shares in TyraTech. As a result of the exercise, the Company ownership in TyraTech changed to 21.18%.

Property_plant_and_equipment_T

Property, plant and equipment (Tables)	9 Months Ended
	Sep. 30, 2014
Summary of Property, Plant and Equipment	'
	Property, plant and equipment at September 30, 2014 and December 31, 2013 consists of the following:
		September 30,			December 31,
		2014			2013
	Land	$	2,458		$	2,458
	Buildings and improvements		14,356			14,167
	Machinery and equipment		106,559			94,184
	Office furniture, fixtures and equipment		4,844			9,717
	Automotive equipment		375			278
	Construction in progress		3,624			10,615
			132,216			131,419
	Less accumulated depreciation		(81,002	)		(78,951	)
		$	51,214		$	52,468

Inventories_Tables

Inventories (Tables)	9 Months Ended
	Sep. 30, 2014
Components of Inventories	'
	The components of inventories consist of the following:
		September 30,		December 31,
		2014		2013
	Finished products	$	148,927	$	126,872
	Raw materials		22,593		12,958
		$	171,520	$	139,830

Segment_Reporting_Tables

Segment Reporting (Tables)	9 Months Ended
	Sep. 30, 2014
Summary of Business Sales Segmentation as per Product	'
	Selective enterprise information is as follows:
		Three Months Ended				Nine Months Ended
		30-Sep				30-Sep
		2014		2013		2014		2013
	Net sales:
	Insecticides	$	24,626	$	49,539	$	105,587	$	167,624
	Herbicides/soil fumigants/fungicides		29,363		28,880		66,220		86,565
	Other, including plant growth regulators		10,711		9,189		23,447		26,108
			64,700		87,608		195,254		280,297
	Non-crop		6,935		9,593		25,789		25,202
		$	71,635	$	97,201	$	221,043	$	305,499
Summary of Business Sales Segmentation as per Location	'
	Net sales:
	US	$	54,552	$	79,425	$	162,602	$	250,367
	International		17,083		17,776		58,441		55,132
		$	71,635	$	97,201	$	221,043	$	305,499

Cash_Dividends_Tables

Cash Dividends (Tables)	9 Months Ended
	Sep. 30, 2014
Cash Dividends	'
	The Company has issued the following cash dividends in the periods covered by this Form 10-Q:
	Declaration Date	Distribution Date	Record Date	Dividend		Total
				Per Share		Paid
	19-Sep-14	October 22, 2014	October 8, 2014	$	0.05	$	1,417
	9-Jun-14	17-Jul-14	3-Jul-14	$	0.05	$	1,420
	10-Mar-14	18-Apr-14	4-Apr-14	$	0.05	$	1,417
	Total			$	0.15	$	4,254
	9-Sep-13	18-Oct-13	4-Oct-13	$	0.05	$	1,415
	10-Jun-13	19-Jul-13	5-Jul-13	$	0.05	$	1,414
	11-Mar-13	19-Apr-13	5-Apr-13	$	0.07	$	1,976
	Total			$	0.17	$	4,805

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	9 Months Ended
	Sep. 30, 2014
Components of Basic and Diluted Earnings Per Share	'
	The components of basic and diluted earnings per share were as follows:
		Three Months Ended				Nine Months Ended
		30-Sep				September 30
		2014		2013		2014		2013
	Numerator:
	Net income attributable to AVD	$	732	$	8,870	$	3,036	$	34,171
	Denominator:
	Weighted average shares outstanding-basic		28,466		28,322		28,422		28,295
	Dilutive effect of stock options and grants		331		567		466		595
			28,797		28,889		28,888		28,890

Indebtedness_Tables

Indebtedness (Tables)	9 Months Ended
	Sep. 30, 2014
Summary of Short-Term and Long-Term Loan Balances in Condensed Consolidated Balance Sheets	'
	The Company has a revolving line of credit and a note payable that together constitute the short-term and long-term loan balances shown in the condensed consolidated balance sheets at September 30, 2014 and December 31, 2013. These are summarized in the following table:
	Indebtedness	September 30, 2014										December 31, 2013
	$000’s	Long-term			Short-term			Total				Long-term				Short-term			Total
	Revolving line of credit	$	95,000		$	—		$	95,000			$	51,550			$	—		$	51,550
	Notes payable		73			71			144				126				69			195
	Total indebtedness	$	95,073		$	71		$	95,144			$	51,676			$	69		$	51,745
Summary of Effect of Derivative Instruments on Statements of Operations and Comprehensive Income	'
	The following tables illustrate the impact of derivatives on the Company’s statements of operations and comprehensive income for the three months and nine months ended September 30, 2014.
	For the three months ended September 30, 2014 and 2013
	Derivatives in ASC 815	Amount of Gain or						Location of Gain or		Amount of Gain or (Loss)								Location of Gain or	Amount of Gain or
	Cash Flow	(Loss) Recognized in						(Loss) Reclassified		Reclassified from Accumulated								(Loss) Recognized in	(Loss)
	Hedging Relationships	OCI on Derivative						from Accumulated		OCI into Income (Effective								Income on Derivative	Recognized
		(Effective Portion)						OCI into Income		Portion)								(Ineffective Portion)	in Income on
								(Effective Portion)											Derivative
																			(Ineffective Portion)
		2014			2013					2014				2013					2014			2013
	Interest rate contracts	$	(1	)	$	(43	)	Interest Expense		$	(146	)		$	(176	)		Interest Expense	$	—		$	—
	Total	$	(1	)	$	(43	)			$	(146	)		$	(176	)			$	—		$	—
	For the nine months ended September 30, 2014 and 2013
	Derivatives in ASC 815	Amount of Gain or						Location of Gain or		Amount of Gain or (Loss)								Location of Gain or	Amount of Gain or
	Cash Flow	(Loss) Recognized in						(Loss) Reclassified		Reclassified from Accumulated								(Loss) Recognized in	(Loss)
	Hedging Relationships	OCI on Derivative						from Accumulated		OCI into Income (Effective								Income on Derivative	Recognized
		(Effective Portion)						OCI into Income		Portion)								(Ineffective Portion)	in Income on
								(Effective Portion)											Derivative
																			(Ineffective Portion)
		2014			2013					2014				2013					2014			2013
	Interest rate contracts	$	(32	)	$	(59	)	Interest Expense		$	(459	)		$	(543	)		Interest Expense	$	(0	)	$	(1	)
	Total	$	(32	)	$	(59	)			$	(459	)		$	(543	)			$	(0	)	$	(1	)
Derivative Liabilities Recognized In Current Installments of Other Liabilities in Condensed Consolidated Balance Sheets	'
	The gross amount of derivative liabilities is equal to the net amount recognized in current installments of other liabilities in the condensed consolidated balance sheets, as shown in the below table:
												Gross Amounts Not Offset in the
												Statement of Financial Position
	Description	Gross			Gross			Net Amounts				Financial				Cash			Net Amount
		Amounts of			Amounts			of Liabilities				Instruments				Collateral
		Recognized			Offset in the			Presented in								Pledged
		Liabilities			Statement			the Statement
					of Financial			of Financial
					Position			Position
	Derivatives by counterparty:
	Bank of the West	$	(138	)	$	—		$	(138	)		$	—			$	—		$	(138	)
	Total	$	(138	)	$	—		$	(138	)		$	—			$	—		$	(138	)

Stock_Based_Compensation_Expen1

Stock Based Compensation Expense (Tables)	9 Months Ended
	Sep. 30, 2014
Summary of Option Activity	'
	Option activity within each plan is as follows:
		Incentive			Weighted Average		Exercisable
		Stock Option			Price Per Share		Weighted
		Plans					Average
							Price
							Per Share
	Balance outstanding, December 31, 2013		561,029		$	7.76	$	7.7
	Options exercised, $7.50		(82,650	)		7.5
	Balance outstanding, March 31, 2014		478,379		$	7.8	$	7.74
	Options exercised, $7.50		(17,500	)		7.5
	Balance outstanding, June 30, 2014		460,879		$	7.81	$	7.77
	Options exercised, $7.50		(1,000	)		7.5
	Balance outstanding, September 30, 2014		459,879		$	7.81	$	7.81
Summary of Stock Options Summarized by Exercise Price	'
	Information relating to stock options at September 30, 2014 summarized by exercise price is as follows:
		Outstanding Weighted Average							Exercisable Weighted
									Average
	Exercise Price Per Share	Shares			Remaining		Exercise		Shares		Exercise
					Life		Price				Price
					(Months)
	Incentive Stock Option Plan:
	$7.50		433,200			74	$	7.5		433,200	$	7.5
	$11.32—$14.75		26,679			71	$	12.9		26,679	$	12.9
			459,879				$	7.81		459,879	$	7.81
Weighted Average Exercise Prices for Options Granted and Exercisable and Weighted Average Remaining Contractual Life for Options Outstanding	'
	The weighted average exercise prices for options granted and exercisable and the weighted average remaining contractual life for options outstanding as of September 30, 2014 was as follows:
		Number			Weighted		Weighted		Intrinsic
		of			Average		Average		Value
		Shares			Exercise		Remaining		(thousands)
					Price		Contractual
							Life
							(Months)
	As of September 30, 2014:
	Incentive Stock Option Plans:
	Outstanding		459,879		$	7.81		74	$	1,603
	Expected to Vest		459,879		$	7.81		74	$	1,603
	Exercisable		459,879		$	7.81		74	$	1,603
Summary of Non-Vested Shares	'
	Restricted Shares—A status summary of non-vested shares as of and for the nine months ended September 30, 2014 is presented below:
		Number			Weighted
		of			Average
		Shares			Grant-
					Date
					Fair Value
	Nonvested shares at December 31, 2013		376,702		$	24.85
	Vested		(1,000	)	$	31.83
	Forfeited		(1,840	)	$	24.23
	Nonvested shares at March 31, 2014		373,862		$	24.83
	Granted		240,724		$	14.81
	Vested		(23,478	)	$	13.84
	Nonvested shares at June 30, 2014		591,108		$	21.19
	Vested		(4,000	)	$	12.16
	Forfeited		(6,104	)	$	14.92
	Nonvested shares at September 30, 2014		581,004		$	21.32
Performance Shares	'
Summary of Non-Vested Shares	'
	Performance Based Shares—A status summary of non-vested performance based shares as of and for the nine months ended September 30, 2014 is presented below:
		Number			Weighted
		of			Average
		Shares			Grant-
					Date
					Fair Value
	Nonvested shares at December 31, 2013		24,637		$	28.43
	Vested		—		$	—
	Forfeited		—		$	—
	Nonvested shares at March 31, 2014		24,637		$	28.43
	Granted		79,270		$	14.23
	Vested		—		$	—
	Forfeited		—		$	—
	Nonvested shares at June 30, 2014		103,907		$	17.6
	Granted		—		$	—
	Vested		—		$	—
	Forfeited		—		$	—
	Nonvested shares at September 30, 2014		103,907		$	17.6

Fair_Value_of_Financial_Instru1

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2014
Cash Flow Hedge Related to Variable Debt Instrument and Outstanding Foreign Currency Derivatives to Hedge Foreign Currency Balances Measured at Fair Value on Recurring Basis, and Balances	'
	The Company’s cash flow hedge related to a variable debt instrument is measured at fair value on a recurring basis, and the balances as of September 30, 2014 and December 31, 2013 (which are included in other liabilities in the condensed consolidated balance sheets) were as follows:
			Fair Value Measurements
			Using Input Type
			Level 1		Level 2		Level 3
	As of September 30, 2014:
	Liability:
	Interest rate derivative financial instruments (1)		$	—	$	138	$	—
	As of December 31, 2013:
	Liability:
	Interest rate derivative financial instruments (1)		$	—	$	564	$	—
	-1	Includes accrued interest expense

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Loss (Tables)	9 Months Ended
	Sep. 30, 2014
Beginning Balance, Annual Activity and Ending Balance of each Component of Accumulated Other Comprehensive Loss	'
	The following table lists the beginning balance, annual activity and ending balance of each component of accumulated other comprehensive loss:
		Interest			FX			Total
		Rate			Translation
		Swap
	Balance, December 31, 2013	$	(340	)	$	(708	)	$	(1,048	)
	Other comprehensive loss before reclassifications		(23	)		51			28
	Amounts reclassified from AOCI		159			—			159
	Balance, March 31, 2014	$	(204	)	$	(657	)	$	(861	)
	Other comprehensive loss before reclassifications		(8	)		92			84
	Amounts reclassified from AOCI		153			—			153
	Balance, June 30, 2014	$	(59	)	$	(565	)	$	(624	)
	Other comprehensive loss before reclassifications		—			(491	)		(491	)
	Amounts reclassified from AOCI		145			—			145
	Balance, September 30, 2014	$	86		$	(1,056	)	$	(970	)

Summary_of_Property_Plant_and_

Summary of Property, Plant and Equipment (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, Gross	$132,216	$131,419
Less accumulated depreciation	-81,002	-78,951
Total Property, plant and equipment	51,214	52,468
Land	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, Gross	2,458	2,458
Buildings and improvements	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, Gross	14,356	14,167
Machinery and equipment	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, Gross	106,559	94,184
Office furniture, fixtures and equipment	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, Gross	4,844	9,717
Automotive equipment	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, Gross	375	278
Construction in progress	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment, Gross	$3,624	$10,615

Property_Plant_and_Equipment_A

Property, Plant and Equipment - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014
Property, Plant and Equipment [Line Items]	'
Elimination of Assets and Accumulated depreciation	$5,150

Components_of_Inventories_Deta

Components of Inventories (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory [Line Items]	'	'
Finished products	$148,927	$126,872
Raw materials	22,593	12,958
Total Inventories	$171,520	$139,830

Segment_Reporting_Additional_I

Segment Reporting - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2014
	Product
Business reportable product	1

Summary_of_Business_Sales_Segm

Summary of Business Sales Segmentation as per Product (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Net Sales:	'	'	'	'
Total Crop	$64,700	$87,608	$195,254	$280,297
Non-crop	6,935	9,593	25,789	25,202
Net sales	71,635	97,201	221,043	305,499
Insecticides	'	'	'	'
Net Sales:	'	'	'	'
Total Crop	24,626	49,539	105,587	167,624
Herbicides/Soil Fumigants/Fungicides	'	'	'	'
Net Sales:	'	'	'	'
Total Crop	29,363	28,880	66,220	86,565
Other, Including Plant Growth Regulators	'	'	'	'
Net Sales:	'	'	'	'
Total Crop	$10,711	$9,189	$23,447	$26,108

Summary_of_Business_Sales_Segm1

Summary of Business Sales Segmentation as per Location (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Net Sales:	'	'	'	'
Net sales	$71,635	$97,201	$221,043	$305,499
US	'	'	'	'
Net Sales:	'	'	'	'
Net sales	54,552	79,425	162,602	250,367
International	'	'	'	'
Net Sales:	'	'	'	'
Net sales	$17,083	$17,776	$58,441	$55,132

Cash_Dividends_Detail

Cash Dividends (Detail) (USD $)	9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Dividends [Line Items]	'	'
Cash dividend declared	$0.15	$0.17
Cash dividends paid	$4,254	$4,805
Third Quarter Dividend	'	'
Dividends [Line Items]	'	'
Cash dividend declaration Date	19-Sep-14	9-Sep-13
Cash dividend distributed date	22-Oct-14	18-Oct-13
Cash dividend record date	8-Oct-14	4-Oct-13
Cash dividend declared	$0.05	$0.05
Cash dividends paid	1,417	1,415
Second Quarter Dividend	'	'
Dividends [Line Items]	'	'
Cash dividend declaration Date	9-Jun-14	10-Jun-13
Cash dividend distributed date	17-Jul-14	19-Jul-13
Cash dividend record date	3-Jul-14	5-Jul-13
Cash dividend declared	$0.05	$0.05
Cash dividends paid	1,420	1,414
First Quarter Dividend	'	'
Dividends [Line Items]	'	'
Cash dividend declaration Date	10-Mar-14	11-Mar-13
Cash dividend distributed date	18-Apr-14	19-Apr-13
Cash dividend record date	4-Apr-14	5-Apr-13
Cash dividend declared	$0.05	$0.07
Cash dividends paid	$1,417	$1,976

Components_of_Basic_and_Dilute

Components of Basic and Diluted Earnings Per Share (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Numerator:	'	'	'	'
Net income attributable to AVD	$732	$8,870	$3,036	$34,171
Denominator:	'	'	'	'
Weighted average shares outstanding-basic	28,466	28,322	28,422	28,295
Dilutive effect of stock options and grants	331	567	466	595
Weighted average shares outstanding-assuming dilution	28,797	28,889	28,888	28,890

Earnings_Per_Share_Additional_

Earnings Per Share - Additional Information (Detail)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Components Of Basic And Diluted Earning Per Share [Line Items]	'	'	'	'
Potentially dilutive stock options to purchase shares	1,207	0	6,183	0

Summary_Revolving_Line_of_Cred

Summary Revolving Line of Credit And Various Notes Payable Constitute Short-Term and Long-Term Loan Balances Together (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Extinguishment of Debt [Line Items]	'	'
Long Term debt	$95,073	$51,676
Short-term	71	69
Total indebtedness	95,144	51,745
Revolving line of credit	'	'
Extinguishment of Debt [Line Items]	'	'
Long Term debt	95,000	51,550
Total indebtedness	95,000	51,550
Notes payable	'	'
Extinguishment of Debt [Line Items]	'	'
Long Term debt	73	126
Short-term	71	69
Total indebtedness	$144	$195

Indebtedness_Additional_Inform

Indebtedness - Additional Information (Detail) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
	Contract
Debt Instrument [Line Items]	'	'
Number of Interest rate swap contract outstanding	1	'
Losses in other comprehensive income expected to be reclassified to earnings	$31,125,000	'
Duration of losses in other comprehensive income expected to be reclassified to earnings	'12 months	'
Fixed interest rate for interest rate swap contract	3.39%	3.39%
Interest rate swap, start date	30-Mar-11	'
Interest rate swap, termination date	31-Dec-14	'
Maximum	'	'
Debt Instrument [Line Items]	'	'
Capacity to increase borrowings under credit agreement	51,156,000	'
Cash Flow Hedging | Interest Rate Swap	'	'
Debt Instrument [Line Items]	'	'
Notional amount of interest rate swap	87,000	'
Revolving Credit Facility	'	'
Debt Instrument [Line Items]	'	'
Senior secured credit facility	200,000,000	'
Senior secured credit facility term	'5 years	'
Revolving Credit Facility | Accordion Feature	'	'
Debt Instrument [Line Items]	'	'
Senior secured credit facility	$100,000,000	'

Summary_of_Effect_of_Derivativ

Summary of Effect of Derivative Instruments on Statements of Operations and Comprehensive Income (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'	'
Amount of Gain or (Loss) Recognized in OCI on Derivative (Effective Portion)	($1)	($43)	($32)	($59)
Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income (Effective Portion)	-146	-176	-459	-543
Amount of Gain or (Loss) Recognized in Income on Derivative (Ineffective Portion)	0	0	0	-1
Designated as Hedging | Cash Flow Hedging | Interest Rate Contracts	'	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'	'
Amount of Gain or (Loss) Recognized in OCI on Derivative (Effective Portion)	-1	-43	-32	-59
Designated as Hedging | Cash Flow Hedging | Interest Rate Contracts | Interest Expense	'	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'	'
Amount of Gain or (Loss) Reclassified from Accumulated OCI into Income (Effective Portion)	-146	-176	-459	-543
Amount of Gain or (Loss) Recognized in Income on Derivative (Ineffective Portion)	$0	$0	$0	($1)

Derivative_Liabilities_Recogni

Derivative Liabilities Recognized in Current Installments of Other Liabilities in Condensed Consolidated Balance Sheets (Detail) (USD $)	Sep. 30, 2014
In Thousands, unless otherwise specified
Derivatives, Fair Value [Line Items]	'
Gross Amounts of Recognized Liabilities	($138)
Gross Amounts Offset in the Statement of Financial Position	'
Net Amounts of Liabilities Presented in the Statement of Financial Position	-138
Financial Instruments	'
Cash Collateral Pledged	'
Net Amount	-138
Bank of the West	'
Derivatives, Fair Value [Line Items]	'
Gross Amounts of Recognized Liabilities	-138
Gross Amounts Offset in the Statement of Financial Position	'
Net Amounts of Liabilities Presented in the Statement of Financial Position	-138
Financial Instruments	'
Cash Collateral Pledged	'
Net Amount	($138)

Summary_of_Option_Activity_Det

Summary of Option Activity (Detail) (USD $)	3 Months Ended
	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Incentive Stock Option Plans, Beginning balance	460,879	478,379	561,029
Incentive Stock Option Plans, Option exercised	-1,000	-17,500	-82,650
Incentive Stock Option Plans, Ending balance	459,879	460,879	478,379
Weighted Average Price Per Share, Beginning balance	$7.81	$7.80	$7.76
Weighted Average Price Per Share, Option exercised	$7.50	$7.50	$7.50
Weighted Average Price Per Share, Ending balance	$7.81	$7.81	$7.80
Exercisable Weighted Average Price Per Share, Beginning balance	$7.77	$7.74	$7.70
Exercisable Weighted Average Price Per Share, Ending balance	$7.81	$7.77	$7.74

Summary_of_Option_Activity_Par

Summary of Option Activity (Parenthetical) (Detail) (USD $)	3 Months Ended
	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Weighted Average Price Per Share, Option exercised	$7.50	$7.50	$7.50

Summary_of_Stock_Options_Summa

Summary of Stock Options Summarized by Exercise Price (Detail) (USD $)	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014
					Incentive Stock Option Plan	Incentive Stock Option Plan	Incentive Stock Option Plan
						Range One	Range Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'	'
Options exercised, Lower Range	'	'	'	'	'	$7.50	$11.32
Options exercised, Upper Range	'	'	'	'	'	'	$14.75
Outstanding Weighted Average, Shares	'	'	'	'	459,879	433,200	26,679
Outstanding Weighted Average, Remaining Life (Months)	'	'	'	'	'74 months	'74 months	'71 months
Outstanding Weighted Average, Exercise Price	$7.81	$7.81	$7.80	$7.76	$7.81	$7.50	$12.90
Exercisable Weighted Average, Shares	'	'	'	'	459,879	433,200	26,679
Exercisable Weighted Average, Exercise Price	$7.81	$7.77	$7.74	$7.70	$7.81	$7.50	$12.90

Weighted_Average_Exercise_Pric

Weighted Average Exercise Prices for Options Granted and Exercisable and Weighted Average Remaining Contractual Life for Options Outstanding (Detail) (USD $)	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2014
In Thousands, except Share data, unless otherwise specified					Incentive Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Number of Shares, Outstanding	459,879	460,879	478,379	561,029	459,879
Number of Shares, Expected to Vest	'	'	'	'	459,879
Number of Shares, Exercisable	'	'	'	'	459,879
Weighted Average Exercise Price, Outstanding	$7.81	$7.81	$7.80	$7.76	$7.81
Weighted Average Exercise Price, Expected to Vest	'	'	'	'	$7.81
Weighted Average Exercisable, Exercise Price	$7.81	$7.77	$7.74	$7.70	$7.81
Weighted Average Remaining Life, Outstanding	'	'	'	'	'74 months
Weighted Average Remaining Contractual Life, Expected to Vest	'	'	'	'	'74 months
Weighted Average Remaining Contractual Life, Exercisable	'	'	'	'	'74 months
Intrinsic Value, Outstanding	'	'	'	'	$1,603
Intrinsic Value, Expected to Vest	'	'	'	'	1,603
Intrinsic Value, Exercisable	'	'	'	'	$1,603

Stock_Based_Compensation_Expen2

Stock Based Compensation Expense - Additional Information (Detail) (USD $)	3 Months Ended				9 Months Ended
	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Performance Shares	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'
Stock-based compensation expense	$101,000	'	'	$92,000	$67,000	$118,000
Number of Shares, Granted	'	79,270	'	'	79,270	24,637
Number of shares vested	'	'	'	'	'	'
Number of years of service before cliff vesting	'	'	'	'	'	'3 years
Weighted Average Grant-Date Fair Value, Granted	'	$14.23	'	'	'	'
Nonvested unamortized stock-based compensation expense, contractual term	'	'	'	'	'2 years 4 months 24 days	'
Cliff vesting date	'	'	'	'	23-May-17	'
Targeted performance percentage	200.00%	'	'	200.00%	200.00%	200.00%
Unamortized stock-based compensation expense	1,404,000	'	'	'	1,404,000	'
Performance Shares | Performance based shares based upon financial performance of earnings before interest and tax ("EBIT") and net sales goal for the period commencing April 1, 2014 and ending December 31, 2016	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'
Weighted Average Grant-Date Fair Value, Granted	'	'	'	'	$14.92	'
Percentage of shares vesting based on Performance	'	'	'	'	80.00%	'
Earnings before income tax goal weight, percentage	'	'	'	'	50.00%	'
Net sales goal weight, percentage	'	'	'	'	30.00%	'
Performance Shares | Performance based shares based upon AVD stock price appreciation over the course of the period commencing April 1, 2014 and ending December 31, 2016	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'
Weighted Average Grant-Date Fair Value, Granted	'	'	'	'	$12.85	'
Percentage of shares vesting based on Performance	'	'	'	'	20.00%	'
Performance Shares | Performance based shares based upon net income and net sales for the period commencing April 1, 2013 and ending December 31, 2015	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'
Percentage of shares vesting based on Performance	'	'	'	'	'	80.00%
Performance Shares | Performance based shares based upon AVD stock price appreciation over the course of the period commencing June 6, 2013 and ending on December 31, 2015	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'
Percentage of shares vesting based on Performance	'	'	'	'	'	20.00%
Restricted Stock	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'
Stock-based compensation expense	1,139,000	'	'	856,000	2,958,000	2,153,000
Nonvested unamortized stock-based compensation expense, value	6,069,000	'	'	'	6,069,000	'
Number of Shares, Granted	'	240,724	'	'	240,724	158,614
Number of shares vested	4,000	23,478	1,000	'	'	8,230
Number of years of service before cliff vesting	'	'	'	'	'3 years	'
Weighted Average Grant-Date Fair Value, Granted	'	$14.81	'	'	$14.81	$31.06
Nonvested unamortized stock-based compensation expense, contractual term	'	'	'	'	'1 year 10 months 24 days	'
Restricted Stock | Share-based Compensation Award, Tranche Three	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'
Number of years of service before cliff vesting	'	'	'	'	'	'3 years
Number of shares expected to vest	'	'	'	148,884	'	148,884
Stock Options	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'
Stock-based compensation expense	0	'	'	201,000	21,000	624,000
Nonvested unamortized stock-based compensation expense, value	$0	'	'	'	$0	'

Summary_of_NonVested_Shares_De

Summary of Non-Vested Shares (Detail) (Restricted Stock, USD $)	3 Months Ended			9 Months Ended
	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Sep. 30, 2014	Sep. 30, 2013
Restricted Stock	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Number of Shares, Beginning balance	591,108	373,862	376,702	376,702	'
Number of Shares, Granted	'	240,724	'	240,724	158,614
Number of Shares, Vested	-4,000	-23,478	-1,000	'	-8,230
Number of Shares, Forfeited	-6,104	'	-1,840	'	'
Number of Shares, Ending Balance	581,004	591,108	373,862	581,004	'
Weighted Average Grant-Date Fair Value, Beginning balance	$21.19	$24.83	$24.85	$24.85	'
Weighted Average Grant-Date Fair Value, Granted	'	$14.81	'	$14.81	$31.06
Weighted Average Grant-Date Fair Value, Vested	$12.16	$13.84	$31.83	'	'
Weighted Average Grant-Date Fair Value, Forfeited	$14.92	'	$24.23	'	'
Weighted Average Grant-Date Fair Value, Ending balance	$21.32	$21.19	$24.83	$21.32	'

Status_Summary_of_NonVested_Sh

Status Summary of Non-Vested Shares (Detail) (Performance Shares, USD $)	3 Months Ended			9 Months Ended
	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Sep. 30, 2014	Sep. 30, 2013
Performance Shares	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Number of Shares, Beginning balance	103,907	24,637	24,637	24,637	'
Number of Shares, Granted	'	79,270	'	79,270	24,637
Weighted Average Grant-Date Fair Value, Granted	'	$14.23	'	'	'
Number of Shares, Vested	'	'	'	'	'
Number of Shares, Forfeited	'	'	'	'	'
Number of Shares, Ending Balance	103,907	103,907	24,637	103,907	'
Weighted Average Grant-Date Fair Value, Beginning balance	$17.60	$28.43	$28.43	$28.43	'
Weighted Average Grant-Date Fair Value, Vested	'	'	'	'	'
Weighted Average Grant-Date Fair Value, Forfeited	'	'	'	'	'
Weighted Average Grant-Date Fair Value, Ending balance	$17.60	$17.60	$28.43	$17.60	'

Legal_Proceedings_Additional_I

Legal Proceedings - Additional Information (Detail)	0 Months Ended	9 Months Ended
	Sep. 27, 2014	Sep. 30, 2014
	Plaintiff
Mark Spence v. A.W. Chesterton Company et al.	'	'
Loss Contingencies [Line Items]	'	'
Date of dismissal	'	22-Sep-14
Number of defendants	'	46
Actions taken by the defendant	'	'Plaintiff dismissed the matter without prejudice on September 22, 2014.
Superior Court of the State of Delaware | Hendler Law Firm | Delaware	'	'
Loss Contingencies [Line Items]	'	'
Number of Lawsuits Filed	'	1
Date of dismissal	'	20-Oct-14
Former Banana Workers	'	'
Loss Contingencies [Line Items]	'	'
Number of lawsuits filed	'	100
Lawsuits filed in United States	'	15
Former Banana Workers | Hendler Law Firm | Delaware	'	'
Loss Contingencies [Line Items]	'	'
Number of claimants	'	2,700
Former Banana Workers | Delaware state court	'	'
Loss Contingencies [Line Items]	'	'
Number of claimants	1	'
Date of dismissal	'	6-Oct-14

Cash_Flow_Hedge_Related_to_Var

Cash Flow Hedge Related to Variable Debt Instrument and Outstanding Foreign Currency Derivatives to Hedge Foreign Currency Balances Measured at Fair Value on Recurring Basis, and Balances (Detail) (Fair Value, Measurements, Recurring, Cash Flow Hedging, Level 2, USD $)	Sep. 30, 2014		Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value, Measurements, Recurring | Cash Flow Hedging | Level 2	'		'
Liability:	'		'
Interest rate derivative financial instruments	$138	[1]	$564	[1]
[1]	Includes accrued interest expense

Beginning_Balance_Annual_Activ

Beginning Balance, Annual Activity and Ending Balance of each Component of Accumulated Other Comprehensive Loss (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'
Beginning Balance	($624)	($861)	($1,048)
Other comprehensive loss before reclassifications	-491	84	28
Amounts reclassified from AOCI	145	153	159
Ending Balance	-970	-624	-861
Interest Rate Swap	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'
Beginning Balance	-59	-204	-340
Other comprehensive loss before reclassifications	'	-8	-23
Amounts reclassified from AOCI	145	153	159
Ending Balance	86	-59	-204
Accumulated Translation Adjustment	'	'	'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'	'	'
Beginning Balance	-565	-657	-708
Other comprehensive loss before reclassifications	-491	92	51
Ending Balance	($1,056)	($565)	($657)

Equity_Investment_Additional_I

Equity Investment - Additional Information (Detail)	0 Months Ended	3 Months Ended		9 Months Ended			1 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 25, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Mar. 25, 2013	Jul. 31, 2014	Jul. 31, 2014	Feb. 28, 2014	Feb. 28, 2014
	USD ($)	USD ($)	USD ($)	USD ($)	USD ($)		TyraTech Inc.	TyraTech Inc.	TyraTech Inc.	TyraTech Inc.
							USD ($)	GBP (£)	USD ($)	GBP (£)
Equity Method Investments [Line Items]	'	'	'	'	'	'	'	'	'	'
Equity investment	$3,687	'	'	'	$3,687	'	'	'	'	'
Equity investment ownership position	'	19.28%	'	19.28%	'	29.27%	'	'	'	'
Shares issued by equity investee	'	'	'	'	'	'	50,000,000	50,000,000	37,391,763	37,391,763
Amount raised by equity investee on shares issued	'	'	'	1,616	929	'	5,900	3,500	3,100	1,870
Gain on dilution of equity method investment	'	'	'	954	'	'	'	'	'	'
Loss from equity method investment	'	-237	-386	-633	-386	'	'	'	'	'
Carrying value of equity investment	'	3,022	'	3,022	'	'	'	'	'	'
Quoted market value of equity investment	'	$6,321	'	$6,321	'	'	'	'	'	'

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Income Taxes [Line Items]	'	'	'	'
Income taxes (benefit) expense	$0	$5,559	$856	$18,500
Effective tax rate	'	'	21.00%	35.00%

Subsequent_event_Additional_In

Subsequent event - Additional Information (Detail) (USD $)	Sep. 30, 2014	Mar. 25, 2013	Oct. 01, 2014	Oct. 01, 2014
In Thousands, except Share data, unless otherwise specified			Subsequent Event	Subsequent Event
Subsequent Event [Line Items]	'	'	'	'
Warrants exercised amount	'	'	$500	'
Warrants exercised shares	'	'	6,155,000	'
Equity investment ownership position	19.28%	29.27%	'	21.18%